Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836894 | 0.85 | OPRM1 (0.39) | ALDH1A1OPRM1OPRK1OPRL1GSK3B | |
| SCHEMBL3524191 | 0.76 | ALDH1A1 (0.48) | ALDH1A1OPRM1OPRK1OPRL1GSK3B | |
| SCHEMBL3523663 | 0.74 | MEN1 (0.44) | ALDH1A1OPRM1OPRK1OPRL1GSK3B | |
| SCHEMBL6402602 | 0.72 | KDM4E (0.36) | ALDH1A1OPRM1OPRK1OPRL1HSD17B10 | |
| SCHEMBL11642156 | 0.71 | OPRM1 (0.43) | ALDH1A1OPRM1OPRK1OPRL1GSK3B | |
| SCHEMBL14487926 | 0.70 | GSK3B (0.50) | GSK3BIDO1KMT2ALMNAPLK4 | |
| SCHEMBL30715017 | 0.69 | KMT2A (0.59) | ALDH1A1GSK3BIDO1MEN1KMT2A | |
| SCHEMBL24447629 | 0.68 | BACE1 (0.67) | OPRM1OPRK1OPRL1IDO1LMNA | |
| SCHEMBL24444155 | 0.68 | BACE1 (0.66) | OPRM1OPRK1OPRL1LMNAMAPT | |
| SCHEMBL11643883 | 0.68 | OPRM1 (0.45) | ALDH1A1OPRM1OPRK1OPRL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004100955-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100957-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0985414-B1 | Medicament for the treatment of glaucoma and ischemic retinopathy | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-0931547-B1 | Piperazinyl-heterocyclic compounds in the treatment of dementia | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6387904-B2 | COMPOUND CONTAINING PIPERAZINE RING | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | ALDH1A1 204/4885OPRM1 2606/4885OPRK1 1757/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | ALDH1A1 1775/4885OPRM1 2394/4885OPRK1 945/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | ALDH1A1 1399/4885OPRM1 1970/4885OPRK1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.